

Supplementary Tab 1. List of primer for detection of genes used in this study.

Target genes	Primer name	Sequence 5'-3'	Size/Annealing temp
KPC-2	bla _{KPC-2} -F	GCTACACCTAGCTCCACCTTC	989bp/53°C
	bla _{KPC-2} -R	ACAGTGGTTGGTAATCCATGC	
NDM-1	bla _{NDM-1} -F	CAGCACACTTCCTATCTC	292bp/52°C
	bla _{NDM-1} -R	CCGCAACCATCCCCTCTT	
IMP	bla _{IMP} -F	CTACCGCAGCAGAGTCTTTG	587bp/58°C
	bla _{IMP} -R	AACCAGTTTTGCCTTACCAT	
VIM-2	bla _{VIM-2} -F	GTAAATTATTGGTCATTTGACCGTC	743bp/52°C
	bla _{VIM-2} -R	CGTTGTGTGCTTGAGCAAGTC	
OXA-48	bla _{OXA-48} -F	TTGGTGGCATCGATTATCGG	744bp/58°C
	bla _{OXA-48} -R	GAGCACTTCTTTTGTGATGGC	

Supplementary Tab 2. Univariate analysis of risk factors for CRE colonization.

Risk factors	CRE rectal carriers (N=54)	non-colonized patients (N=320)	<i>P</i> value (OR[CI 95%])
Age, years			
18-60	22 (40.7)	152 (47.5)	0.357 (0.760 [0.423-1.365])
60-80	15 (27.8)	130 (40.6)	0.073 (0.562 [0.298-1.062])
>80	16 (29.6)	28 (8.8)	<0.001 (4.391 [2.178-8.852])
Sex, male	36 (66.7)	169 (52.8)	0.058 (1.787 [0.974-3.279])
Hospitalization history			
in the 6 months before screening	37(68.5)	190 (59.4)	0.203 (1.489 [0.804-2.757])
3 or more co-morbid conditions	28 (51.9)	42 (13.1)	<0.001 (7.128[3.817-13.313])
APACHE II score \geq 21	33 (61.1)	111 (34.7)	<0.001 (2.959[1.634-5.357])
Carriage or infection with another MDRO	32 (59.3)	31 (9.7)	<0.001(13.560[7.028-26.162])
Invasive procedures	31 (57.4)	180 (56.3)	0.874 (1.048[0.585-1.878])
Carbapenem use	15 (27.8)	32 (10.0)	<0.001 (3.462 [1.721-6.961])
Cefoperazone/sulbactam use	14(25.9)	83(25.9)	0.999 (0.999 [0.518-1.930])
Piperacillin/tazobactam use	6(11.1)	51(15.9)	0.361 (0.659[0.268-1.622])
Vancomycin use	6(11.1)	15(4.7)	0.058 (2.542[0.940-6.871])

Hormone use	3(5.6)	11(3.4)	0.448 (1.652[0.446-6.127])
PPI use	27(50.0)	153(47.8)	0.766 (1.092[0.613-1.943])
